Navigation Links
Advanced Biologics Opens New and Expanded Headquarters in Carlsbad, California
Date:9/10/2013

CARLSBAD, Calif., Sept. 10, 2013 /PRNewswire/ -- Advanced Biologics, developers and marketers of OsteoAMP® Allogeneic Morphogenetic Protein, is pleased to announce the expansion and relocation of their company headquarters to Carlsbad, CA.

The new office location will allow Advanced Biologics to better meet its expanded sales and distribution network and prepare for new and upcoming product introductions.  The modern, 15,000-square-foot facility adds additional office space, warehousing capabilities, and enhanced R&D areas.

"This move highlights the successful growth our company has experienced over the last few years," stated President, Amit Govil. "This much needed additional space will allow us to; maximize our operational efficiencies, allow for expansion into new and exciting opportunities and provide a better work environment for current and future staff."

Advanced Biologics' new office address is 2800 Roosevelt Street, Carlsbad, CA 92008. Phone and fax numbers will remain the same.

About Advanced Biologics

Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC has been recognized three times as 'Best New Technology' during the Orthopedics This Week Spine Technology Awards. www.advancedbiologics.com


'/>"/>
SOURCE Advanced Biologics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Advanced Care Veterinary Services Proves Stem Cell Therapy May Be the Best Weapon in Fighting Pet Pain Due to Arthritis
2. Advanced Tissue Services Offering Discounts on Bio-specimens Utilized in Academic Research
3. 2013 NASA Advanced Technology Phase I Concepts Selected For Study
4. Primary Progression-Free Survival Endpoint Met in Phase III Study of Nintedanib Plus Docetaxel in Second-Line Advanced NSCLC
5. Syngenta Opens Unique $72 Million Advanced Crop Lab
6. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
7. Amphora Research Systems welcomes Advanced Polymer Monitoring Technologies
8. Photonics-Enabled Tools for Forensic Investigations to be Advanced at SPIE DSS
9. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Tauriga Sciences, Inc. (OTCQB:  ... sciences company, today announced that its stockholders approved an ... stock of the Company from 1,000,000,000 to 2,500,000,000 at ... 2015 at the Law Offices of Nixon Peabody LLP ... Meeting, there were 480,655,929 shares of common stock represented ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... Pa. , July 28, 2015 ... and Drug Administration has accepted for review the company,s ... factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia ... primary endpoints. Hemophilia A ... defective factor VIII; nearly all affected patients are male. ...
(Date:7/28/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 28, ... ) today announced its financial results for the ... ®  sales grew nearly 300% as compared to ... was first launched," said Roger Jeffs, Ph.D., United ... in Orenitram sales was due to an increase ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... The DELFIA time-resolved fluorescence assay for inhibition of poly(ADP-ribose) ... the inhibition of PARP-activated incorporation of biotinylated nicotinamide adenine ... The method is a convenient way to screen test ... and secondary screening. , ...
... , ... lanthanide ions has long been a challenge for the spectroscopist. Methods to counter the extremely ... Protective ligands to reduce vibrational quenching effects by XH moieties (X ... Deuterated solvents (also to reduce quenching effects of XH). , ...
... , ... A phosphorimeter integral to the SPEX FLUOROMAX -P or as ... uncover important information on various systems of chemical and biochemical interest, by ... <P,>This Application Note describes an example, using the SPEX ...
Cached Biology Technology:A DELFIA Assay for Inhibition of PARP 2A DELFIA Assay for Inhibition of PARP 3Time gated separation of lanthanide luminescence 2Phosphorescence lifetime measured using the SPEX phosphorimeter 2
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... An evaluation team led by the Drexel University School ... that customers of full-service restaurants use nutritional labeling on ... "This is the first field-based study of mandatory menu ... in calories between customers who dined at labeled restaurants ...
... of the fact that the first antibiotics were discovered ... encephalitis and meningitis are still serious diseases for humans ... estimates that there are more than 8 million new ... and that more than 300,000 of these are due ...
... new analysis method, researchers at Karolinska Institutet and Science for ... hundred novel human gene regions that code for proteins. A ... linked to cancer. The expectation is now that this recently ... Nature Methods , will open up a whole new field ...
Cached Biology News:Drexel study: Consumers order a less unhealthy meal when the menu has nutritional labeling 2Drexel study: Consumers order a less unhealthy meal when the menu has nutritional labeling 3Bacteria use lethal cytotoxins to evade antibiotic treatment 2Protein coding 'junk genes' may be linked to cancer 2
... The potential applications for the use of ... gene expression via the RNA interference,(RNAi) pathway ... and molecular biology fields. siRNA for experimental ... or enzymatically, and then transfected into the ...
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
Acetylcholinesterase (human brain, AChE)...
C1-inhibitor (C1-INH)...
Biology Products: